Novo Nordisk A/S left open the door for additional work on its pill version of Ozempic for Alzheimer’s disease after a pair ...

Eli Lilly and Novo Nordisk have announced they are working on new oral drugs that can be used for type-2 diabetes and weight ...

Eli Lilly announced trial results for its weight-loss medication, orforglipron, in August. Orforglipron is a once-daily oral ...

In two studies, semaglutide failed to slow decline in thousands of people with early stages of Alzheimer's disease.

Eli Lilly’s new oral GLP-1 drug, orforglipron, is shaping up to be a major development in obesity treatment, showing nearly ...

An oral version of the GLP-1 drug semaglutide failed to significantly slow the disease's progression compared to a placebo.

Oral semaglutide—a key ingredient in obesity and diabetes drugs Ozempic and Wegovy—didn’t slow Alzheimer’s disease in two ...

A first-of-its-kind oral drug boosts muscle metabolism to improve blood sugar and body composition is now headed into larger ...

Novo, which in September said it secured Indian regulatory approval to import and sell Ozempic, on Thursday said it hoped to ...

A new oral GLP-1 receptor agonist, orforglipron, is revolutionizing weight management by offering a needle-free alternative ...

Next-generation pills and monthly injectables promise more choice, fewer side effects and broader health benefits.

A pill version of A/S’s Ozempic failed to slow the progression of Alzheimer’s disease in a pair of long-shot studies that ...